EXPERIENCE YOU CAN TRUST
The firm specializes in complex, commercial litigation. The firm's principal, Joshua H. Grabar, has been involved in some of the largest class actions of the last two decades.
DEDICATION YOU CAN RELY ON
We take pride in providing effective and aggressive representation. Our reputation and history of success speaks for itself and drives lasting client relationships. We are here for you.
LET'S WORK TOGETHER
If you have suffered a financial loss as a result of securities fraud, price-fixing or consumer fraud, you can rest assured that we are on your side. If you are a business seeking to avoid unnecessary legal liability, or reduce the costs of compliance, we are your solution.
latest blog
Grabar Law Office In the News:Â Â Alto Neuroscience Execs Sued Over Rosy Drug Claims
By Grabar Law |
An Alto Neuroscience investor claims CEO Amit Etkin and other directors overstated the efficacy of the psychiatric biotech company’s lead drug candidate for treating major depressive disorder, according to a lawsuit filed Tuesday in California federal court that alleges the company’s stock price plummeted when the truth came out. From the time of Alto’s $120…
Read More 
Grabar Law Office In the News:Â Â Marijuana Vape Antitrust Actions Consolidated In Calif.
By Grabar Law |
Five proposed antitrust class actions brought by buyers of CCell brand cannabis vape accusing the Chinese manufacturers and U.S. distributors of organizing a price-fixing scheme will be consolidated in California federal court, the U.S. Judicial Panel on Multidistrict Litigation has determined. In an Oct. 1 transfer order, the panel found all the actions involve common…
Read More 
Grabar Law Office In the News:Â Â DOJ Asks for Stay in PVC Antitrust Case Amid Criminal Probe
By Grabar Law |
The U.S. Department of Justice is asking an Illinois federal court to pause discovery in a case accusing polyvinyl chloride pipe manufacturers of using a commodity pricing service to exchange information and fix prices while a grand jury investigates the alleged activity. The DOJ filed a motion to intervene and stay discovery in the consolidated…
Read More 
Grabar Law Office In the News: Biotech Replimune Faces Derivative Suit Over Trial Claims
By Grabar Law |
Executives and directors of biotechnology company Replimune Group Inc. face shareholder derivative claims that they concealed issues affecting a clinical trial of one of the company’s lead immunotherapy candidates. In a complaint in Boston federal court Tuesday, Replimune investor John Chea claimed the company’s CEO Sushil Patel, Chief Financial Officer Emily Hill, board Chair Philip…
Read More